Drugmaker GlaxoSmithKline LLC will pay $22 million to West Virginia—one of the largest settlements the state has ever reached with a drug company—to resolve claims that GSK unlawfully promoted prescription drugs, including its diabetes treatment Avandia (rosiglitazone), West Virginia Attorney General Patrick Morrisey (R) announced June 12.
The settlement puts to rest allegations that GSK concealed cardiovascular risks associated with Avandia and fraudulently promoted its superiority as a diabetes drug. GSK didn’t admit any liability in connection with the settlement.
Morrisey said revenue from the settlement will be used to “shore up several state funds that benefit West Virginians and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.